MetaCap

MaxCyte Quarterly Income Statement

NASDAQ: MXCTHealth CareBiotechnology: Commercial Physical & Biological ResarchUSD

1.37+0.09 (+7.03%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

MaxCyte revenue and earnings

In the quarter ended Sep 30, 2026, MaxCyte generated $10.2 million in revenue, up 48.7% from the same quarter a year earlier. MaxCyte reported a net loss of $4.8 million, compared with a loss of $12.4 million a year earlier. Gross margin was 83.4% (up from 76.6%) and operating margin -59.5%.

Diluted earnings per share came in at -$0.05.

Summary generated from market data by MetaCap's automated system. Methodology

MaxCyte income statement (quarterly)

MaxCyte quarterly income statement
Quarter (USD)Q3 20262026-09-30Q2 20262026-06-30Q1 20262026-03-31Q4 20252025-12-31Q3 20252025-09-30Q2 20252025-06-30Q1 20252025-03-31Q4 20242024-12-31Q3 20242024-09-30Q2 20242024-06-30Q1 20242024-03-31Q4 20232023-12-31
Revenue10.15M7.27M9.65M7.30M6.83M8.51M10.39M8.69M8.16M10.43M11.34M15.66M
Revenue growth (YoY)+48.66%-14.53%-7.11%-16.02%-16.35%-18.43%-8.39%-44.51%+2.00%+15.33%+32.25%+26.10%
Cost of Revenue1.68M1.68M1.57M1.61M1.60M1.52M1.50M2.28M1.93M1.49M1.40M1.57M
Gross Profit8.47M5.60M8.08M5.69M5.23M6.99M8.89M6.41M6.24M8.94M9.94M14.09M
Operating Expenses14.51M15.83M14.27M16.92M19.38M21.21M21.19M19.31M20.29M20.91M22.21M22.19M
Research & Development2.87M4.25M3.86M3.33M5.32M6.27M5.90M4.61M5.32M5.62M6.68M5.84M
Selling, General & Admin10.77M10.62M9.39M8.99M9.96M13.87M14.22M13.68M13.95M14.26M14.47M15.28M
Operating Income-6.04M-10.23M-6.18M-11.23M-14.15M-14.23M-12.29M-12.90M-14.05M-11.97M-12.28M-8.10M
Other Income (Expense)1.28M1.36M1.44M1.63M1.73M1.87M2.03M2.30M2.50M2.59M2.75M2.82M
Pretax Income-4.76M-8.87M-4.75M-9.60M-12.42M-12.36M-10.26M-10.60M-11.56M-9.38M-9.53M-5.28M
Net Income-4.76M-8.87M-4.75M-9.60M-12.42M-12.36M-10.26M-10.60M-11.56M-9.38M-9.53M-5.28M
Net Income growth (YoY)————————————
EPS (Basic)-0.05-0.08-0.04-0.08-0.12-0.12-0.10-0.10-0.11-0.09-0.09-0.05
EPS (Diluted)-0.05-0.08-0.04-0.08-0.12-0.12-0.10—-0.11-0.09—-0.05
Shares Outstanding (Basic)103.54M106.82M106.88M—106.61M106.40M105.95M—105.11M104.64M104.09M—
Shares Outstanding (Diluted)103.54M106.82M106.88M—106.61M106.40M105.95M—105.11M104.64M104.09M—
EBITDA-5.14M-9.25M-5.14M-10.15M-13.08M-13.13M-11.20M-11.84M-12.99M-10.89M-11.16M-6.99M
Gross Margin83.41%76.96%83.74%77.95%76.63%82.14%85.59%73.76%76.38%85.73%87.63%89.96%
Operating Margin-59.51%-140.72%-64.09%-153.78%-207.19%-167.24%-118.33%-148.41%-172.13%-114.76%-108.23%-51.68%
Net Margin-46.91%-122.05%-49.22%-131.45%-181.81%-145.26%-98.76%-121.90%-141.56%-89.89%-83.99%-33.69%

This table shows 12 quarterly periods of MaxCyte's income statement, from Q3 2026 back to Q4 2023, across 19 line items including revenue, cost of revenue, gross profit. Values in USD; B = billions, M = millions. Fiscal periods follow MXCT's reporting calendar. What is a income statement?

More financial data